Short Interest in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Declines By 17.3%

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 39,800 shares, a decline of 17.3% from the November 30th total of 48,100 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily trading volume, of 338,600 shares, the short-interest ratio is presently 0.1 days.

Phio Pharmaceuticals Trading Down 7.7 %

NASDAQ:PHIO traded down $0.16 on Friday, hitting $1.93. 255,504 shares of the stock were exchanged, compared to its average volume of 117,227. The stock has a fifty day moving average of $2.68 and a 200-day moving average of $3.46. The stock has a market cap of $2.04 million, a PE ratio of -0.18 and a beta of 1.49. Phio Pharmaceuticals has a fifty-two week low of $1.53 and a fifty-two week high of $10.35.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.